4 months Fin Min, 2 Laser sesh with Exosomes 50 y/o 6/12/2025
A 50-year-old user shares progress on hair loss treatment after 4 months using finasteride and minoxidil, along with 2 laser sessions with exosomes. The user hopes to restore the crown and mid-scalp areas.
View this post in the Community →
Similar Community Posts Join
5 / 5 resultscommunity microneedle, any long term users damage?
Microneedling is effective for hair growth, especially when combined with finasteride and minoxidil, but concerns exist about potential long-term skin damage. Users report increased collagen and elastin deposition, but the long-term effects on the scalp remain uncertain.
community 5 months fin/min with 3 sessions of laser therapy and Exosomes
The conversation discusses hair regrowth after 5 months of using finasteride and minoxidil, along with 3 sessions of laser therapy and exosomes. The user is hopeful about regaining their bangs.
community Doctor said exosome therapy is so painful that one of his patients tried to choke him mid-session
The user visited a dermatologist for hair loss and was prescribed finasteride and minoxidil tablets, along with a caffeine hair serum. They decided against painful and costly treatments like PRP and exosome therapy, opting instead to stick with medications and possibly accept going bald.
community Two transplants later, loads of misinformation & a rollercoaster of a journey I'm finally on the mend.
A user shared their hair loss journey, detailing two hair transplants and various treatments including finasteride, minoxidil, PRP, and exosomes. They found success with a regimen of topical dutasteride, minoxidil, derma stamping, and caffeine shampoo, leading to improved hair growth and satisfaction.
community Exosome PRP combined with Dutasteride and Oral Minoxidil?
The user has been using Dutasteride and oral Minoxidil for hair loss but hasn't seen desired results and is considering Advanced PRP with autologous exosomes. Some users suggest these treatments are scams, while others discuss increasing Dutasteride dosage or exploring other options like low-level laser therapy.
Related Research
6 / 6 results
research A decade of progress in androgenetic alopecia management: Emerging therapies and multimodal strategies
This review reports that the treatment of androgenetic alopecia is shifting from single therapies to personalized, multimodal approaches incorporating both traditional and emerging pharmacologics, regenerative strategies, nutraceuticals, cosmeceuticals, and device-based interventions, with combination regimens showing improved outcomes.
research Emerging pharmacotherapies and regenerative solutions for promoting hair growth for androgenetic alopecia
This study reviews new treatments for androgenetic alopecia, including cell-derived exosomes and investigational drugs, which show potential to improve hair density and quality but require more rigorous and standardized trials to confirm efficacy and safety.
research Updates in Treatment for Androgenetic Alopecia
This review discusses current and emerging treatments for androgenetic alopecia, covering mechanisms, efficacy, and safety of both androgen-targeted and non-androgen-targeted approaches, but reports no new clinical results.
research Advances in hair growth
This review discusses recent advances in understanding hair growth mechanisms and reviews current and emerging therapies, but it presents no new clinical results.
research Status of research on the development and regeneration of hair follicles
This review examines the mechanisms of hair follicle development and regeneration, discussing current hair loss treatments and emerging therapies like low-level laser therapy and stem cell therapy, which the authors suggest show promise in managing hair loss.
research Treatment options for androgenetic alopecia: Efficacy, side effects, compliance, financial considerations, and ethics
This review discusses treatment options for androgenetic alopecia, highlighting the need for personalized, evidence-based approaches but reports no new clinical results.